Intellia Therapeutics (NTLA) Gains from Sales and Divestitures (2016 - 2026)
Intellia Therapeutics (NTLA) reported Gains from Sales and Divestitures of $1.5 million for Q1 2026, up 0.53% year-over-year from $1.5 million in Q1 2025, and down 26.91% on a QoQ basis from $2.1 million in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Gains from Sales and Divestitures data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Gains from Sales and Divestitures rose 0.53% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 0.53% YoY) and the FY2025 annual result came in at $2.1 million, up 44.87% from the prior year.
- Gains from Sales and Divestitures retreated to $1.5 million in Q1 2026 per NTLA's latest filing, from $2.1 million in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $2.1 million in Q4 2025 and bottomed at $54666.0 in Q1 2022.
- The 5-year median for Gains from Sales and Divestitures is $1.0 million (2024), against an average of $946269.9.
- The widest annual swing landed in 2023, when Gains from Sales and Divestitures surged 550.69%; it then increased 0.53% in 2026.
- Tracing NTLA's Gains from Sales and Divestitures over 5 years: stood at $147674.0 in 2022, then jumped by 358.48% to $677055.0 in 2023, then soared by 111.75% to $1.4 million in 2024, then surged by 44.87% to $2.1 million in 2025, then decreased by 26.91% to $1.5 million in 2026.
- Per Business Quant, the three latest NTLA Gains from Sales and Divestitures figures stand at $1.5 million (Q1 2026), $2.1 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.52 Mn |
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 677,055.00 |
| Dec 31, 2023 | 677,055.00 |
| Sep 30, 2023 | 597,610.00 |
| Sep 30, 2023 | 597,610.00 |
| Jun 30, 2023 | 493,878.00 |
| Jun 30, 2023 | 493,878.00 |
| Mar 31, 2023 | 342,025.00 |
| Mar 31, 2023 | 342,025.00 |
| Dec 31, 2022 | 147,674.00 |
| Dec 31, 2022 | 147,674.00 |
| Sep 30, 2022 | 91,843.00 |
| Sep 30, 2022 | 91,843.00 |
| Jun 30, 2022 | 91,181.00 |
| Jun 30, 2022 | 91,181.00 |
| Mar 31, 2022 | 54,666.00 |
| Mar 31, 2022 | 54,666.00 |
| Dec 31, 2021 | 119,715.00 |
| Dec 31, 2021 | 119,715.00 |
| Sep 30, 2021 | 50,946.00 |
| Sep 30, 2021 | 50,946.00 |
| Jun 30, 2021 | 26,235.00 |
| Jun 30, 2021 | 26,235.00 |
| Dec 31, 2020 | 82,829.00 |
| Dec 31, 2020 | 82,829.00 |
| Dec 31, 2019 | 37,198.00 |
| Dec 31, 2019 | 37,198.00 |
| Sep 30, 2019 | 37,198.00 |
| Sep 30, 2019 | 37,198.00 |
| Jun 30, 2019 | 36,462.00 |
| Jun 30, 2019 | 36,462.00 |
| Mar 31, 2019 | 29,881.00 |
| Mar 31, 2019 | 29,881.00 |
| Dec 31, 2018 | 411,372.00 |
| Dec 31, 2018 | 411,372.00 |
| Sep 30, 2018 | 378,033.00 |
| Sep 30, 2018 | 378,033.00 |
| Jun 30, 2018 | 298,229.00 |
| Jun 30, 2018 | 298,229.00 |
| Mar 31, 2018 | 149,846.00 |
| Mar 31, 2018 | 149,846.00 |
| Dec 31, 2017 | 791,571.00 |
| Dec 31, 2017 | 791,571.00 |
| Sep 30, 2017 | 558,760.00 |
| Sep 30, 2017 | 558,760.00 |
| Jun 30, 2017 | 374,204.00 |
| Jun 30, 2017 | 374,204.00 |
| Mar 31, 2017 | 186,917.00 |
| Mar 31, 2017 | 186,917.00 |
| Dec 31, 2016 | 864,230.00 |
| Dec 31, 2016 | 864,230.00 |
| Sep 30, 2016 | 675,329.00 |
| Sep 30, 2016 | 675,329.00 |
| Jun 30, 2016 | 461,508.00 |
| Jun 30, 2016 | 461,508.00 |
| Mar 31, 2016 | 170,807.00 |
| Mar 31, 2016 | 170,807.00 |